ABCG2 and cancer: In addition, it has been reported that VS-4718 could antagonize the multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells through competitively interacting with ABCB1 and ABCG2 and affecting the activity of ABCB1 and ABCG2, which indicated that VS-4718 combines with other anticancer drugs may antagonize the multidrug resistance [49,50,51,52].